Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, Adil I. Daud, F. Stephen Hodi, Jedd D. Wolchok, Tara C. Mitchell, Peter Hersey, Roxana Dronca, Richard W. Joseph, Celine Boutros, Le Min, Georgina V. Long, Jacob Schachter, Igor Puzanov, Reinhard Dummer, Jianxin Lin, Nageatte Ibrahim, Scott J. Diede, Matteo S. Carlino, Anthony M. Joshua

Open source

DOI: 10.1016/j.ejca.2020.11.010
Published: 2021-02
Container: European Journal of Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2020.11.010,
  title = {Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma},
  author = {Caroline Robert and Wen-Jen Hwu and Omid Hamid and Antoni Ribas and Jeffrey S. Weber and Adil I. Daud and F. Stephen Hodi and Jedd D. Wolchok and Tara C. Mitchell and Peter Hersey and Roxana Dronca and Richard W. Joseph and Celine Boutros and Le Min and Georgina V. Long and Jacob Schachter and Igor Puzanov and Reinhard Dummer and Jianxin Lin and Nageatte Ibrahim and Scott J. Diede and Matteo S. Carlino and Anthony M. Joshua},
  year = {2021},
  journal = {European Journal of Cancer},
  doi = {10.1016/j.ejca.2020.11.010},
  url = {https://doi.org/10.1016/j.ejca.2020.11.010}
}

RIS

TY  - JOUR
TI  - Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
AU  - Caroline Robert
AU  - Wen-Jen Hwu
AU  - Omid Hamid
AU  - Antoni Ribas
AU  - Jeffrey S. Weber
AU  - Adil I. Daud
AU  - F. Stephen Hodi
AU  - Jedd D. Wolchok
AU  - Tara C. Mitchell
AU  - Peter Hersey
AU  - Roxana Dronca
AU  - Richard W. Joseph
AU  - Celine Boutros
AU  - Le Min
AU  - Georgina V. Long
AU  - Jacob Schachter
AU  - Igor Puzanov
AU  - Reinhard Dummer
AU  - Jianxin Lin
AU  - Nageatte Ibrahim
AU  - Scott J. Diede
AU  - Matteo S. Carlino
AU  - Anthony M. Joshua
PY  - 2021
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2020.11.010
UR  - https://doi.org/10.1016/j.ejca.2020.11.010
ER  -

APA

Robert, C., Hwu, W., Hamid, O., Ribas, A., Weber, J. S., Daud, A. I., Hodi, F. S., Wolchok, J. D., Mitchell, T. C., Hersey, P., Dronca, R., Joseph, R. W., Boutros, C., Min, L., Long, G. V., Schachter, J., Puzanov, I., Dummer, R., Lin, J., Ibrahim, N., Diede, S. J., Carlino, M. S., & Joshua, A. M. (2021). Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2020.11.010

Source records

crossref · retrieved 2026-09-26T02:07:52.618Z